Suppr超能文献

一项针对具有挑战性的腹腔镜腹侧或切口疝修补队列,采用含Sepra技术的长期生物可吸收补片的前瞻性多中心试验(ATLAS试验)。

A prospective, multicenter trial of a long-term bioabsorbable mesh with Sepra technology in cohort of challenging laparoscopic ventral or incisional hernia repairs (ATLAS trial).

作者信息

Hope William W, El-Ghazzawy Adel G, Winterstein Brad A, Blatnik Jeffrey A, Davis S Scott, Greenberg Jacob A, Sanchez Noel C, Pauli Eric M, Tseng Daniel M, LeBlanc Karl A, Roberts Kurt E, Bower Curtis E, Parra-Davila Eduardo, Roth J Scott, Deeken Corey R, Smith Eric F

机构信息

New Hanover Regional Medical Center, Department of Surgery, Wilmington, NC, United States.

Overlake Medical Center, Department of Surgery, Bellevue, WA, United States.

出版信息

Ann Med Surg (Lond). 2021 Dec 6;73:103156. doi: 10.1016/j.amsu.2021.103156. eCollection 2022 Jan.

Abstract

BACKGROUND

This prospective, multicenter, single-arm, open-label study evaluated P4HB-ST mesh in laparoscopic ventral or incisional hernia repair (LVIHR) in patients with Class I (clean) wounds at high risk for Surgical Site Occurrence (SSO).

METHODS

Primary endpoint was SSO requiring intervention <45 days. Secondary endpoints included: surgical procedure time, length of stay, SSO >45 days, hernia recurrence, device-related adverse events, reoperation, and Quality of Life at 1, 3, 6, 12, 18, and 24-months.

RESULTS

120 patients (52.5% male), mean age of 55.0 ± 14.9 years, and BMI of 33.2 ± 4.5 kg/m received P4HB-ST mesh. Patient-reported comorbid conditions included: obesity (86.7%), active smoker (45.0%), COPD (5.0%), diabetes (16.7%), immunosuppression (2.5%), coronary artery disease (7.5%), chronic corticosteroid use (2.5%), hypoalbuminemia (0.8%), advanced age (10.0%), and renal insufficiency (0.8%). Hernia types were primary ventral (44.2%), primary incisional (37.5%), recurrent ventral (5.8%), and recurrent incisional (12.5%). Patients underwent LVIHR in laparoscopic (55.8%) or robotic-assisted cases (44.2%), mean defect size 15.7 ± 28.3 cm, mean procedure time 85.9 ± 43.0 min, and mean length of stay 1.0 ± 1.4 days. There were no SSOs requiring intervention beyond 45 days, n = 38 (31.7%) recurrences, n = 22 (18.3%) reoperations, and n = 2 (1.7%) device-related adverse events (excluding recurrence).

CONCLUSION

P4HB-ST mesh demonstrated low rates of SSO and device-related complications, with improved quality of life scores, and reoperation rate comparable to other published studies. Recurrence rate was higher than expected at 31.7%. However, when analyzed by hernia defect size, recurrence was disproportionately high in defects ≥7.1 cm (43.3%) compared to defects <7.1 cm (18.6%). Thus, in LVIHR, P4HB-ST may be better suited for small defects. Caution is warranted when utilizing P4HB-ST in laparoscopic IPOM repair of larger defects until additional studies can further investigate outcomes.

摘要

背景

本前瞻性、多中心、单臂、开放标签研究评估了P4HB-ST补片在手术部位感染(SSO)高风险的I类(清洁)伤口患者的腹腔镜腹侧或切口疝修补术(LVIHR)中的应用。

方法

主要终点是术后<45天需要干预的SSO。次要终点包括:手术时间、住院时间、术后>45天的SSO、疝复发、与器械相关的不良事件、再次手术以及术后1、3、6、12、18和24个月的生活质量。

结果

120例患者(52.5%为男性),平均年龄55.0±14.9岁,体重指数33.2±4.5kg/m²,接受了P4HB-ST补片治疗。患者报告的合并症包括:肥胖(86.7%)、现吸烟者(45.0%)、慢性阻塞性肺疾病(5.0%)、糖尿病(16.7%)、免疫抑制(2.5%)、冠状动脉疾病(7.5%)、长期使用糖皮质激素(2.5%)、低白蛋白血症(0.8%)、高龄(10.0%)和肾功能不全(0.8%)。疝的类型包括原发性腹侧疝(44.2%)、原发性切口疝(37.5%)、复发性腹侧疝(5.8%)和复发性切口疝(12.5%)。患者接受了腹腔镜(55.8%)或机器人辅助(44.2%)的LVIHR,平均缺损大小为15.7±28.3cm,平均手术时间为85.9±43.0分钟,平均住院时间为1.0±1.4天。术后45天以上无需要干预的SSO,38例(31.7%)复发,22例(18.3%)再次手术,2例(1.7%)发生与器械相关的不良事件(不包括复发)。

结论

P4HB-ST补片显示出较低的SSO和与器械相关的并发症发生率,生活质量评分有所改善,再次手术率与其他已发表的研究相当。复发率为31.7%,高于预期。然而,按疝缺损大小分析,缺损≥7.1cm的复发率(43.3%)明显高于缺损<7.1cm的复发率(18.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/791e/8689054/ab743b57a41f/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验